Catumaxomab
Catumaxomab,[1] sold under the brand name Removab among others, is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer.The drug is used for the treatment of malignant ascites in people with EpCAM-positive cancer if a standard therapy is not available.The usual treatment of malignant ascites is to puncture the peritoneum to let the accumulated fluid drain out.Catumaxomab was developed by Trion Pharma, based on preliminary work by the Helmholtz Zentrum München.[8] Fresenius Biotech conducted clinical trials and filed the drug for approval with the European Medicines Agency (EMA).
Monoclonal antibodyTrifunctional antibodyTargetDrugs.comRoutes ofadministrationintraperitoneal infusionATC codeL01FX03Legal statusCAS NumberDrugBankChemSpidermalignantascitesmetastasizingFreseniusGermanyperitoneal cavityperitoneumintraperitonealnauseaNSAIDsanalgeticsantipyreticscytokinesT lymphocyteantigen-presenting cellmacrophagenatural killer celldendritic cellheavy chainlight chainFc receptorHelmholtz Zentrum Münchenclinical trialsEuropean Medicines AgencyCommittee for Medicinal Products for Human UseTargeted cancer therapyantineoplastic agentsmonoclonal antibodiesReceptor tyrosine kinaseHER1/EGFRCetuximabPanitumumabHER2/neuPertuzumabTrastuzumab+hyaluronidaseTrastuzumab emtansineTrastuzumab deruxtecanZanidatamabEdrecolomabVEGF-ABevacizumabLeukemialymphomalymphoidGlofitamabElranatamabMosunetuzumabIbritumomabObinutuzumabOfatumumabRituximabTositumomabBrentuximabAlemtuzumabmyeloidGemtuzumab ozogamicinAmivantamabAtezolizumabAvelumabAxatilimabBelantamab mafodotinBermekimabBlinatumomabCemiplimabCosibelimabDaratumumabDinutuximab betaDostarlimabDurvalumabElotuzumabEnfortumab vedotinEpcoritamabInotuzumab ozogamicinIpilimumabIsatuximabLoncastuximab tesirineMirvetuximab soravtansineMogamulizumabMoxetumomab pasudotoxNaxitamabNecitumumabNivolumab+relatlimabOlaratumabOportuzumab monatoxPembrolizumabPolatuzumab vedotinRamucirumabRetifanlimabSacituzumab govitecanSerplulimabSugemalimabTafasitamabTalquetamabTarlatamabTeclistamabTislelizumabTisotumab vedotinToripalimabTremelimumabZenocutuzumabZolbetuximabTyrosine kinase inhibitorsAfatinibAumolertinibBrigatinibDacomitinibErlotinibGefitinibIcotinibLazertinibMobocertinibOlmutinib